Avila Therapeutics™ is pioneering a method to generate and develop new medicines that achieve ‘protein silencing’ based on the proprietary Avilomics™ platform. These medicines, called covalent drugs, strongly and resiliently bond to disease-causing proteins, resulting in therapies that are highly effective against a broad spectrum of human diseases.

The covalent bonding mechanism of Avila’s drugs has the unique property of effectively ‘silencing’ disease-causing proteins by establishing a strong and enduring ‘bond’ – exceeding the more temporary ‘binding’ of conventional drugs – to completely shut down the activity of and silence a disease-causing protein. Avila’s covalent drugs have exceptional therapeutic benefits because they are highly targeted, are effective against mutations and have a long duration of action.

Avila is developing a pipeline of novel, protein silencing drugs with a current focus on viral infection, cancer and autoimmune diseases. Led by an interdisciplinary team of successful industry professionals and investors with extensive experience in the life sciences sector, Avila will create medicines to improve patient outcomes and quality of life in a fundamentally new way.

[ back to home ]